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Background: Obesity and related metabolic abnormalities, including excess oxidative stress and chronic inflammation,
are associated with colorectal carcinogenesis. Astaxanthin, a xanthophyll carotenoid found in aquatic animals, is known
to possess antioxidant, anti-inflammatory, and antineoplastic properties. The present study examined the effects of
astaxanthin on the development of azoxymethane (AOM)-induced colonic premalignant lesions in C57BL/KsJ-db/db
(db/db) obese mice.
Method: Male db/db mice were administered 4 weekly subcutaneous injections of AOM (15 mg/kg body weight) from
5 weeks of age and subsequently, from 1 week after the last injection of AOM, were fed a diet containing 200 ppm
astaxanthin throughout the experiment (8 weeks).
Result: The development of colonic premalignant lesions, i.e., aberrant crypt foci and β-catenin accumulated crypts,
was significantly inhibited in mice treated with astaxanthin than in mice fed the basal diet. Astaxanthin administration
markedly reduced urinary levels of 8-OHdG and serum levels of d-ROMs, which are oxidative stress markers, while
increasing the expression of mRNA for the antioxidant enzymes GPx1, SOD1, and CAT in the colonic mucosa of
AOM-treated db/db mice. The expression levels of IL-1β, IL-6, F4/80, CCL2, and CXCL2 mRNA in the colonic mucosa of
AOM-treated mice were significantly decreased by astaxanthin. Dietary feeding with astaxanthin also resulted in a
reduction in the numbers of NF-κB- and PCNA-positive cells that were increased by AOM exposure, in the colonic
epithelium.
Conclusion: These findings suggest that astaxanthin inhibits the development of colonic premalignant lesions in an
obesity-related colorectal carcinogenesis model by reducing oxidative stress, attenuating chronic inflammation, and
inhibiting NF-κB activation and cell proliferation in the colonic mucosa. Astaxanthin, therefore, may be a potential
candidate as a chemoprevention agent against colorectal carcinogenesis in obese individuals.
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Obesity, a growing health concern worldwide, is a result of
excess energy intake and insufficient exercise. Obesity is as-
sociated with increased risk of diseases with high mortality,
such as ischemic heart disease, stroke, and cancer [1]. In
particular, the risk of colorectal cancer (CRC), which is the* Correspondence: shimim-gif@umin.ac.jp
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unless otherwise stated.third most common malignancy in men and the second in
women, globally [2], is especially higher when combined
with obesity [3-5]. The five-year survival for early stage
CRC is 80–90% but decreases to 65% for all stages [6].
Therefore, in addition to early detection and treatment,
chemoprevention with effective agents is considered ex-
tremely important for the comprehensive management of
CRC [7,8].
Several pathophysiological mechanisms linking obesity
and the development of CRC have been elucidated, in-
cluding the emergence of insulin resistance, imbalancehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chronic inflammation [3-5]. Obese and diabetic mice are
susceptible to chemically induced colon tumorigenesis [9].
Diet-induced obesity significantly promotes colon tumor
development in mice [10]. On the other hand, recent stud-
ies have demonstrated that certain types of phytochemicals
such as curcumin and (−)-epigallocatechin gallate inhibit
the development of obesity-related colorectal carcinogen-
esis in mice by attenuating chronic inflammation [11,12].
Administration of angiotensin-converting enzyme inhibitor
also suppresses the early phase of colorectal carcinogenesis
in diabetic and hypertensive rats by attenuating inflamma-
tion and oxidative stress [13]. These reports suggest that
targeting obesity-related metabolic abnormalities including
chronic inflammation and oxidative stress using phyto-
chemicals and specific agents is an effective strategy for
preventing CRC development in obese individuals [3].
Astaxanthin, a conventional red-colored xanthophyll, is
an oxygenated carotenoid derivative occurring naturally in
a wide variety of living organisms including microalgae,
fungi, salmon, trout, shrimp, and some birds [14,15]. Astax-
anthin has been shown to exert numerous pharmacological
effects due to its antioxidant, anti-inflammatory, antidi-
abetic, and antineoplastic properties [8,14,15]. Supple-
mentation with astaxanthin actually decreased oxidative
stress and inflammation in a clinical trial [16]. In pre-
clinical animal studies, dietary astaxanthin was found to
significantly inhibit chemically induced colorectal [17,18],
urinary bladder [19], and oral carcinogenesis [20]. In par-
ticular, anti-inflammatory activity is one of the key mecha-
nisms by which astaxanthin prevents colitis-related CRC
development [17,18].
C57BL/KsJ-db/db (db/db) mice, which lack the long form
of the leptin receptor, develop hyperphagic obesity and dia-
betes [21]. Interestingly, the development of colonic prema-
lignant lesions induced by azoxymethane (AOM), a colonic
carcinogen widely used to produce preneoplastic and neo-
plastic colonic lesions that mimic those observed human
colon, is significantly enhanced in db/db mice [22]. A pre-
clinical animal model using AOM and db/db mice [22] has
proved useful in investigating specific agents for their ability
to prevent inflammation-related colorectal carcinogenesis
caused by obesity [11,12,23-25]. In the present study, we in-
vestigated the effects of astaxanthin on the development of
colonic premalignant lesions, i.e., aberrant crypt foci (ACF)
and β-catenin accumulated crypts (BCAC) [26-28], using
this obesity-related colorectal carcinogenesis model, with




Four-week-old male db/db mice were purchased from
Japan SLC, Inc. (Shizuoka, Japan) and were maintainedhumanely at the Gifu University Life Science Research
Center in accordance with the Institutional Animal Care
Guidelines. AOM was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Astaxanthin from Haematococcus
pluvialiswas was supplied by Fuji Chemical Industry
(Toyama, Japan).
Experimental procedure
All experimental protocols involving animals were ap-
proved by the Animal Research Committee, Gifu Uni-
versity Graduate School of Medicine. Forty male db/db
mice were divided into the following 4 groups: untreated
control (n = 10); 200 ppm astaxanthin alone (n = 10);
AOM alone (n = 10); and, AOM and 200 ppm astax-
anthin (n = 10). At 5 weeks of age, mice in AOM alone
group and AOM+ astaxanthin group were injected with
AOM (15 mg/kg body weight) subcutaneously once a
week for 4 weeks. None treatment group and AOM
alone group were fed the basal diet CRF-1 (the formula
of Charles River, Oriental Yeast, Tokyo, Japan) through-
out the experiment. The composition of the CRF-1 diet
was as follows: 8.1 g/100 g water, 22.6 g/100 g protein,
5.6 g/100 g fat, 6.6 g/100 g minerals, 3.3 g/100 g fiber,
and 53.8 g/100 g carbohydrates. Astaxanthin alone
group and AOM+ astaxanthin group were fed the basal
diet supplemented with 200 ppm astaxanthin for
8 weeks, starting 1 week after the last injection of AOM.
The dosage of astaxanthin was determined according to
a previous report [18]. Food intakes in all groups were
measured daily, while body weights were recorded once
a week during the study. At the termination of the study
(17 weeks of age), all mice were killed, and the develop-
ment of ACF and BCAC was analyzed.
Identification and quantification of ACF and BCAC
The numbers of ACF and BCAC were determined ac-
cording to standard procedures [12,23,24,29]. After fix-
ing flat in 10% buffered formalin for 24 hours, we
stained the colons with methylene blue (0.5% in distilled
water) to count ACF. The number of ACF was recorded
along with the number of aberrant crypts (ACs) in each
focus. The data are expressed per colon. The distal parts
of the colon (1 cm from anus; mean area, 0.7 cm2/colon)
were then resected and embedded in paraffin, and a total
of 20 serial sections (each 4 μm thick) per mouse were
cut by an en face preparation to identify BCAC intramu-
cosal lesions [12,23,24].
Immunohistochemical analyses for β-catenin, proliferating
cell nuclear antigen, and nuclear factor-κB
Immunohistochemistry for β-catenin was performed
using the labeled streptavidin-biotin method (LSAB Kit;
DAKO, Glostrup, Denmark) to count the number of
BCAC [12,23,24]. The primary antibody for β-catenin
Table 1 Primers sequences
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used at a final dilution of 1:1000. Immunohistochemical
staining for proliferating cell nuclear antigen (PCNA),
which is a G1-to-S phase marker, and for phospho-
nuclear factor-κB (NF-κB) p65 were run on histological
sections to estimate cell proliferative activity and NF-κB
activity, respectively, in the colonic crypts [11,23], using
the LSAB Kit (DAKO) with primary antibodies, anti-
PCNA antibody (a final dilution of 1:100, Santa Cruz
Biotechnology, Dallas, TX, USA) and anti-phospho-NF-
κB p65 antibody (a final dilution of 1:50, Ser276; Cell
Signaling Technology, Danvers, MA, USA). The PCNA-
labeling index (%) and positive cell index (%) for
phospho-NF-κB p65 were determined based on previous
methods [11,23].
RNA extraction and quantitative real-time reverse
transcription-PCR analysis
Total RNA was isolated from scraped colonic mucosa of
experimental mice using the RNeasy Mini Kit (QIAGEN,
Venlo, Netherlands). The cDNA was synthesized from
0.2 μg of total RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA). A quantitative real-time reverse transcription-PCR
(RT-PCR) analysis was performed using a LightCycler Nano
(Roche Diagnostics, Indianapolis, IN, USA) with FastStart
Essential DNA Green Master (Roche Diagnostics). The
PCR cycling conditions were 95°C for 10 min, followed by
45 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 15 s.
The sequences of specific primers amplifying tumor necro-
sis factor (TNF)-α, interleukin (IL)-1β, IL-6, F4/80, chemo-
kine (C-C motif) ligand (CCL)2, chemokine (C-X-C motif)
ligand (CXCL)2, glutathione peroxidase (GPx)1, superoxide
dismutase (SOD)1, catalase (CAT) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) genes were obtained
from Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/
primer-blast/; Table 1). The expression levels of TNF-α, IL-
1β, IL-6, F4/80, CCL2, CXCL2, GPx1, SDO1, and CAT genes
were normalized to the GAPDH gene expression levels.
Clinical chemistry
Blood samples were collected from the inferior vena
cava at sacrifice after 6 hours of fasting for chemical
analyses. The serum concentrations of insulin (Shibayagi,
Gunma, Japan), glucose (BioVision Research Products,
Mountain View, CA, USA), adiponectin (R&D Systems,
Minneapolis, MN, USA), leptin (R&D Systems), trigly-
ceride (Wako, Osaka, Japan), and TNF-α (R&D Systems)
were determined using an enzyme immunoassay, ac-
cording to the manufacturer’s protocol.
Oxidative stress analysis
Urine 8-hydroxy-2’-deoxyguanosine (8-OHdG) levels
were measured using an enzyme-linked immunosorbentassay kit (NIKKEN SEIL, Shizuoka, Japan). Serum levels
of hydroperoxide, a marker for oxidative stress, were de-
termined using the derivatives of reactive oxygen metab-
olites (d-ROMs) test (FREE Carpe Diem, Diacron
International s.r.l., Grosseto, Italy) [30].
Statistical analyses
The measures are presented as mean ± SD and were sta-
tistically analyzed using the GraphPad InStat software
program, Version 3.05 (GraphPad Software, San Diego,
CA, USA) for Macintosh. One-way analysis of variance
(ANOVA) was used to compare groups. If the ANOVA
analysis indicated significant differences, the Tukey–
Kramer multiple comparisons test was performed to
compare the mean values among the groups. The differ-
ences were considered significant when the two-sided
P value was less than 0.05.
Results
General observations
During the experiment, dietary feeding with astaxanthin
did not cause any clinical symptoms. As listed in Table 2,
the mean body weight of the AOM alone group was
lower than that of AOM-untreated control group (group
1, P < 0.05) at the termination of the experiment. This
might be due to the toxicity of AOM, as observed in













1 None 10 51.2 ± 3.2 6.7 ± 0.9 5.9 ± 0.5
2 Astaxanthin 10 50.3 ± 3.0 6.1 ± 0.8 5.5 ± 0.8
3 AOM alone 10 46.7 ± 4.0c 5.6 ± 0.7c 5.6 ± 0.8
4 AOM + astaxanthin 10 48.6 ± 3.4 6.0 ± 0.6 5.1 ± 0.7
aMean ± SD.
bWhite adipose tissue of the periorchis and retroperitoneum.
cSignificantly different from group 1 by Tukey-Kramer Multiple Comparison
Test (P < 0.05).
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weight (g/100 g body weight) of AOM alone group was
also significantly lower than that of none treatment group
(P < 0.05). No significant differences were observed in the
mean relative weights of adipose tissue among the groups.
Histopathological examination of the liver, kidney, and
spleen confirmed the absence of toxicity of dietary astax-
anthin (data not shown).
Effects of astaxanthin on AOM-induced ACF and BCAC
formation in experimental mice
ACF (Figure 1A) developed only in the colons of mice






Figure 1 Effects of astaxanthin on AOM-induced ACF and
BCAC formation in experimental mice. (A) Representative
morphology of ACF (arrows) induced by AOM, revealed by methylene
blue staining in an AOM alone-injected mouse (left panel) and
AOM + astaxanthin-treated mouse (right panel). (B) β-catenin
immunohistochemistry of BCAC (broken line) that developed in
an AOM alone-injected mouse (left panel) and AOM + astaxanthin-
treated mouse (right panel).colon, aberrant crypts/colon, and large ACFs/colon were
significantly reduced by astaxanthin administration (Table 3;
P < 0.05). Moreover, the number of BCAC (Figure 1B),
which also developed only in the colons of AOM-treated
mice, markedly decreased when these mice were fed
astaxanthin-containing diets (Table 3; P < 0.05), indicating
that two types of precursor lesions for CRC were sup-
pressed by astaxanthin administration. These findings
suggest that astaxanthin prevented the early phase of
obesity-related colorectal carcinogenesis.Effects of astaxanthin on systemic oxidative stress and
expression levels of GPx1, SOD1, and CAT mRNA in the
colonic mucosa of experimental mice
Oxidative stress is implicated in obesity-related colorectal
tumorigenesis [4]. Therefore, we determined the levels of
oxidative stress and antioxidant biomarkers in the experi-
mental mice. AOM injection significantly increased the
levels of urinary 8-OHdG (Figure 2A; P < 0.05), which re-
flects DNA damage induced by oxidative stress, and serum
d-ROMs (Figure 2B; P < 0.01), marker for hydroperoxide
levels of serum, as compared to those observed in the con-
trol group. However, the level of 8-OHdG significantly
decreased with astaxanthin administration (Figure 2A;
P < 0.05). As shown in Figure 2C, the expression of GPx1
mRNA, which encodes an antioxidant enzyme, was reduced
by AOM injection (P < 0.05), but astaxanthin significantly
increased the expression of GPx1, as well as of SOD1 and
CAT, both of which encode antioxidant enzymes, in the
colonic mucosa of db/dbmice treated with AOM (P < 0.05).Effects of astaxanthin on serum levels of TNF-α and
expression levels of TNF-α, IL-1β, IL-6, F4/80, CCL2, and
CXCL2 mRNA in the colonic mucosa of experimental mice
Chronic inflammation plays a critical role in the pathogen-
esis of obesity and CRC development [4,31]. Therefore,
the effect of astaxanthin on the levels of inflammatory me-
diators including TNF-α, IL-1β, IL-6, F4/80, CCL2, and
CXCL2 in experimental mice was examined. Serum levels
of TNF-α were significantly higher in the AOM-injected
mice (Figure 3A; P < 0.05), but not in the astaxanthin-
treated mice, than those in the control mice. As shown in
Figure 3B, there was a marked increase in the expression
levels of TNF-α, IL-1β, IL-6, and F4/80 (P < 0.05 compared
to the untreated control group) in the colonic mucosa of
group treated with AOM alone. However, astaxanthin ad-
ministration significantly decreased the expression of IL-
1β, IL-6, and F4/80 mRNA in the colonic mucosa of the
AOM-treated db/db mice (P < 0.05). The expression of
CCL2 and CXCL2, which are associated with colorectal
carcinogenesis [32-34], in the colonic mucosa of the
AOM-treated db/db mice was also significantly decreased
by astaxanthin treatment (P < 0.05).
Table 3 Effects of astaxanthin on AOM-induced and BCAC formations in db/db mice
Group no. Treatment No. of mice Total no. of
ACF/colona
Total no. of ACF/colonaCrypt
multiplicity (Average no. of
crypts/foci)a




1 None 10 0 0 0 0
2 Astaxanthin 10 0 0 0 0
3 AOM alone 10 11.9 ± 7.2 27.4 ± 12.5 1.4 ± 1.5 5.9 ± 2.6
4 AOM + astaxanthin 10 4.3 ± 2.7c 13.5 ± 5.7c 0.3 ± 0.6c 1.0 ± 1.0c
aMean ± SD.
b“Large ACFs” are ACFs with four or more aberrant crypts.
c Significantly different from group 3 by Tukey-Kramer Multiple Comparison Test (P < 0.05).
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http://www.biomedcentral.com/1471-230X/14/212Effects of astaxanthin on NF-κB activity and cell proliferative
activity in the colonic mucosa of experimental mice
NF-κB activation is critically involved in the progression
of inflammation and the activation of cell proliferation
in colonic mucosa [35]. Therefore, the effects of astax-
anthin on NF-κB activity and cell proliferative activity
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Figure 2 Effects of astaxanthin on levels of urinary 8-OHdG, serum le
CAT mRNA in experimental mice. (A) At the time of killing, urine sample
were measured by enzyme-linked immunosorbent assay. (B) Hydroperoxid
RNA was isolated from the colonic mucosa of experimental mice, and the
quantitative real-time RT-PCR using specific primers. Values are expressed amice. The indices of phospho-NF-κB p65-positive cells,
which were increased by AOM injection in the colonic
epithelium, were significantly reduced by astaxanthin
treatment (Figure 4A; P < 0.001 for each comparison).
As shown in Figure 4B, astaxanthin treatment also sig-
nificantly decreased the PCNA-labeling indices of non-
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vels of d-ROMs, and colonic expression levels of GPx1, SOD1, and
s were collected from experimental mice, and levels of urinary 8-OHdG
e levels in the serum were determined by the d-ROM test. (C) Total
expression levels of GPx1, SOD1, and CAT mRNA were examined by
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Figure 3 Effects of astaxanthin on serum levels of TNF-α and colonic expression levels of TNF-α, IL-1β, IL-6, F4/80, CCL2, and CXCL2
mRNA in experimental mice. (A) The serum concentration of TNF-α was measured by enzyme immunoassay. (B) Total RNA was isolated from
the colonic mucosa of experimental mice, and the expression levels of TNF-α, IL-1β, IL-6, F4/80, CCL2, and CXCL2 mRNA were examined by quantitative
real-time RT-PCR using specific primers. Values are expressed as mean ± SD (triple assays). *P < 0.05
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that astaxanthin significantly inhibits NF-κB activity and
cell proliferation in the colonic mucosa of AOM-treated
db/db mice.
Effects of astaxanthin on serum parameters in
experimental mice
Diabetes, dyslipidemia, and adipokine imbalance, which
are complications often associated with obesity, are
involved in colorectal tumorigenesis [3-5]. Therefore,
serum parameters associated with these metabolic disor-
ders were assessed. AOM exposure did not affect either
serum levels of adiponectin, triglycerides, glucose, andinsulin or the value of QUICKI, a useful index of insulin
sensitivity [36], in experimental mice (Table 4). The
serum level of leptin was significantly elevated by AOM
irrespective of astaxanthin administration (P < 0.05). None
of these metabolic parameters had been altered by astax-
anthin administration at the end of this study.
Discussion
Obesity, which is one of the most serious healthcare
problems worldwide, is a significant risk factor for the
development of CRC [4,5]. Oxidative stress and chronic
inflammation are key mechanisms linking obesity and
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Figure 4 Effects of astaxanthin on the NF-κB activity and cell proliferative activity in the colonic mucosa of experimental mice.
Sections of the colon were stained with (A) anti-phospho-NF-κB p65 or (B) anti-PCNA antibodies, respectively. Representative photographs
from each group are shown in the upper panels. The positive cell indices, which were determined by counting (A) phospho-NF-κB p65-positive cells
or (B) PCNA-positive cells in the colonic crypts, are shown in the lower panels. Original magnification, 200×. Bars, SD of triplicate assays.
*P < 0.001, **P < 0.01
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upregulate the expression of various pro-inflammatory cy-
tokines including TNF-α and IL-6, and this is critically
associated with CRC development because these cytokines
stimulate tumor growth and progression [31,39]. The
results of the present study show that astaxanthin exertsTable 4 Serum parameters in the experimental mice
Group no. treatment 1 Nonea 2 Astaxant
Glucose (mg/dl) 110.8 ± 18.4 110.2 ± 18.3
Insulin (nM/ml) 131.8 ± 53.3 120.7 ± 35.3
Quicki 0.249 ± 0.005 0.253 ± 0.00
Adiponectin (ng/ml) 52.2 ± 2.0 53.3 ± 1.1
Leptin (ng/ml) 5.3 ± 0.3 4.6 ± 0.5
Triglyceride (mg/dl) 91.6 ± 32.7 91.6 ± 35.4
aMean ± SD.
bSignificantly different from group 1 by Tukey-Kramer Multiple Comaprison Test (P
cSignificantly different from group 3 by Tukey-Kramer Multiple Comaprison Test (P <preventive effects on the development of the AOM-
induced colonic premalignant lesions ACF [26,27] and
BCAC [28] in db/db obese mice, mainly through the reduc-
tion of oxidative stress and attenuation of inflammation.
Saturated fatty acids from obesity-induced lipolysis are
capable of activating macrophages and thereby activatinghina 3 AOM alonea 4 AOM+ astaxanthina
97.6 ± 24.6 83.6 ± 25.1
203.1 ± 51.9 174.9 ± 47.3
7 0.238 ± 0.007 0.238 ± 0.011
57.1 ± 13.8 57.5 ± 3.2
9.9 ± 0.3b 8.3 ± 0.5c
82.7 ± 24.6 90.2 ± 50.1
< 0.05).
0.05).
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activation of genes encoding pro-inflammatory factors
including IL-1β and IL-6 [39]. IL-1β plays a key role in
obesity-induced inflammation [39] and inflammation-
related carcinogenesis by modulating the gene expres-
sion involved in proliferation, survival, and angiogenesis
[40]. The expression of CCL2, which is associated with
infiltration and migration of tumor-related macrophages,
has been demonstrated in several tumor tissues includ-
ing CRC [32,33]. In addition, CXCL2, an inflammatory
cytokine, has been shown to participate in the early
phase of colorectal carcinogenesis [34]. In the present
study, the expression levels of IL-1β, IL-6, F4/80, CCL2,
and CXCL2 mRNA were decreased by astaxanthin in the
experimental mice. These findings indicate that overex-
pression of these inflammatory mediators, which connect
obesity and carcinogenesis, may be one of the critical
targets of astaxanthin in preventing the development of
obesity-related CRC. These findings are also consistent
with those from a previous study showing that feeding
with astaxanthin significantly suppressed colitis and
colitis-related colorectal carcinogenesis by inhibiting
NF-κB activation, decreasing the expression of IL-1β
and IL-6, and suppressing cell proliferation in mice
[18]. In particular, NF-κB signaling pathway is regarded
as one of the key targets of astaxanthin to exert chemo-
preventive effects [41].
Obesity and chronic inflammation are often accom-
panied with increased generation of reactive oxygen spe-
cies (ROS), which are derivatives of molecular oxygen
such as superoxide and hydrogen peroxide. These deriv-
atives can induce mutagenic changes and may damage
DNA repair proteins, resulting in cancer development
[40,42]. Cancer cells are also known to cause oxidative
stress by generating ROS and modulating antioxidant
enzymes [43]. In the present study, oxidative stress
markers, including urinary levels of 8-OHdG and serum
levels of d-ROMs, were significantly suppressed, while
the expression levels of GPx1, SOD1, and CAT mRNA,
which encode antioxidant enzymes, in the colonic mu-
cosa were increased by astaxanthin intake in AOM-
injected db/db mice. These results strongly indicate that
attenuation of oxidative stress and recuperation from
high oxidation state via antioxidative effects are critical
mechanisms by which astaxanthin suppressed the occur-
rence of premalignant lesions, ACF and BCAC, in obese
mice. It should be mentioned that astaxanthin has even
been called a super-antioxidant because it is a superior
antioxidant and scavenger of free radicals as compared
with other carotenoids such as β-carotene [44].
Epidemiologically, it is still unclear whether the intake
of carotenoids such as astaxanthin is associated with a re-
duced risk of CRC development. The results of random-
ized trials using β-carotene supplementation provided noevidence to support an effect of carotenoids on CRC che-
moprevention [45,46]. Rather, intervention trials using
high-dose β-carotene supplements showed an increase in
the incidence of lung cancer in high-risk patients, like
smokers and/or workers exposed to asbestos [47,48]. On
the other hand, astaxanthin has been demonstrated to be
safe in several human clinical trials [16,49,50]. Moreover,
astaxanthin supplementation has positive effects on lipid
profiles and oxidative stress in overweight and obese sub-
jects, at least in part by activating the antioxidant defense
system [49,50]. Taken together, these observations suggest
that obese individuals, who are at high-risk of developing
CRC and colorectal adenomas [5], may be appropriate
subjects for interventional trials using astaxanthin for the
prevention of colorectal tumorigenesis.
Previous reports using metabolic syndrome animal
models have shown that astaxanthin reduces insulin resist-
ance, recovers insulin sensitivity, and increases serum
levels of adiponectin [51,52]. A double-blind randomized
controlled trial also reported that astaxanthin consump-
tion significantly increases blood adiponectin levels [53].
Furthermore, targeting insulin resistance and adipokine
imbalance are suggested to be effective methods of
preventing obesity-related colorectal tumorigenesis [3].
Therefore, we initially expected that astaxanthin would in-
hibit the development of ACF and BCAC in the AOM-
treated db/db mice by ameliorating insulin resistance and
improving adipokine imbalance. However, abnormalities
in serum levels of glucose, insulin, adiponectin, and leptin
were not improved by astaxanthin administration in this
study. We suggest that this was likely due to the duration
of the experiment (8 weeks) and the particular animal
model studied, because previous studies demonstrating ef-
fects of astaxanthin on insulin sensitivity were long-term
studies (22 weeks) [51] and the animals were not genetic-
ally obese [51,52]. Our results were consistent with an-
other study investigating the effect of astaxanthin on the
apoptosis of retinal ganglion cells using db/db mice, in
which insulin resistance was not improved by astaxanthin,
but apoptosis of retinal ganglion cells was attenuated via
the suppression of oxidative stress [54]. Future long-term
studies should be conducted to confirm that astaxanthin
inhibits the early phase of obesity-related colon tumori-
genesis by improving insulin resistance and the imbalance
of adipokines in several animal models. In our experimen-
tal model, astaxanthin suppressed the development of
obesity-related colorectal tumorigenesis by targeting oxi-
dative stress, inflammation, and cell proliferation.
Conclusion
In summary, the results from this study showed that reduc-
tion of oxidative stress and attenuation of inflammation in
the colonic mucosa are crucial mechanisms by which astax-
anthin acts to prevent the early phase of obesity-related
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http://www.biomedcentral.com/1471-230X/14/212colorectal carcinogenesis. Since the risk of CRC increases
with obesity and obesity-related metabolic abnormalities,
which are impending health crises worldwide, targeting
obesity-related metabolic abnormalities, including chronic
inflammation and induction of oxidative stress, may be an
attractive and effective strategy for preventing the develop-
ment of CRC in obese individuals. Astaxanthin seems to be
a potentially effective and viable candidate for this purpose
because this agent attenuates chronic inflammation while
reducing oxidative stress without causing side effects.
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